Table 2.
Drug Treatment During Study Course
| Drug, % | Admission | Discharge | After 3 Months | After 12 Months |
|---|---|---|---|---|
| Ca-antagonists | 24.1 | 33.8 | 28.8 | 29.7 |
| Beta-blockers | 88.4 | 88.4 | 87.3 | 87.9 |
| Ivabradine | 1.5 | 6.6 | 1.8 | 2.4 |
| Amiodaron | 4.5 | 2.5 | 3.0 | 3.0 |
| ACE inhibitors | 52.8 | 45.2 | 42.4 | 37.6 |
| ARBs | 28.1 | 39.4 | 36.9 | 40.0 |
| Sacubitril/valsartan | 1.5 | 2.5 | 5.4 | 5.5 |
| MRA | 27.5 | 27.9 | 26.8 | 24.4 |
| Statins | 75.4 | 83.3 | 79.4 | 76.4 |
| Aspirin | 71.9 | 67.7 | 66.1 | 63.6 |
| P2Y12 inhibitors | 56.3 | 56.6 | 50.0 | 21.2 |
| OACs | 31.2 | 34.3 | 31.5 | 30.9 |
| Insulin | 2.5 | 14.1 | 13.3 | 10.9 |
| OADs | 21.1 | 24.7 | 23.0 | 23.6 |
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; OAK, oral anticoagulation; OAD, oral antidiabetics; MRA, mineralocorticoid receptor antagonist.